Algisyl-LVR is a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle as a result of a myocardial infarct, mitral valve regurgitation, ischemia, arrhythmias, and/or other disorders. The product consists of an injectable proprietary biopolymer that is administered directly into strategic areas of the left ventricle muscle. 12-18 injections are made into the left ventricle wall, and the biopolymer thi